At LGC we advocate the principles of the 3Rs (Replacement, Reduction and Refinement) framework for performing more humane animal research. As such we have developed our capabilities for the bioanalysis of preclinical microsamples (≤50μL), be it from capillary liquid sampling or dried matrices.
Clinical trials involving vulnerable patient groups or diseases that are acute in nature can also benefit from the deployment of patient centric microsampling that enables remote or at home sampling. The team at LGC have created optimisation and validation protocols to ensure the rapid development of bioanalytical methods for the measurement of pharmaceuticals, biopharmaceuticals and biomarkers from patient centric sampling devices.
The smaller sample sizes and dried matrices involved with microsampling potentially offer faster turnaround, ease of sampling, storage, and shipment. Additionally, the use of patient centric devices can improve subject recruitment, retention and the ability to run trials in geographically challenging environments.
As an active member of the European Bioanalytical Forum microsampling project and Patient Centric Sampling Interest Group (PCSIG), LGC has experience with a range of techniques and devices including:
- Dried blood spots
- Capillary liquid microsampling
- Volumetric absorptive microsampling (VAMS)
Our Drug Development Solutions team can advise on which technique may be most appropriate for your study and can support studies employing microsampling devices with regulatory method development, validations and sample analysis along with any bridging studies that may be required.
LGC’s Immunogenicity Centre of Excellence has utilised microsampling for our COVID-19 antibody assay. Using Neoteryx’s Mitra® microsampling device samples can be collected at home without the need for a healthcare professional.
Our Scientific Director, Mike Wright, was recently spoke to Neoteryx for their Microsamplify Podcast. Listen to the full interview.